

Cosentyx (secukinumab)

Override(s)	Approval Duration
Prior Authorization Quantity Limit	1 year

Medications	Quantity Limit*
Cosentyx (secukinumab) 75 mg/0.5 mL Prefilled Syringe*	1 syringe per 28 days
Cosentyx (secukinumab) 150 mg/mL Sensoready pen*	1 pen per 28 days
Cosentyx (secukinumab) 150 mg/mL Sensoready Pen 2-Pack*^	1 pack (2 x 150 mg/mL pens)
Cosentyx (secukinumab) 150 mg/mL Prefilled Syringe*	1 syringe per 28 days
Cosentyx (secukinumab) 150 mg/mL Prefilled Syringe 2-Pack*^	1 pack (2 x 150 mg/mL syringes)
Cosentyx (secukinumab) 300 mg/2mL UnoReady Pen/Prefilled Syringe*^	1 pen/syringe per 28 days
Cosentyx (secukinumab) 125 mg/ 5 mL single-dose vial*	3 vials every 4 weeks
	Dosing Limit
Cosentyx (secukinumab) 125 mg/ 5 mL single-dose vial*	1.75 mg/kg, up to a max limit of 300 mg [3 vials], every 4 weeks

*FDA recommended dosing for Adult Psoriatic Arthritis (PsA) without coexistent plaque psoriasis (Ps), Ankylosing Spondylitis (AS) or non-radiographic axial spondyloarthritis (nr-axSpA): Optional loading doses of 150 mg at weeks 0, 1, 2, 3, 4; maintenance dose of 150 mg every 4 weeks; continued active PsA/AS maintenance dose of 300 mg every 4 weeks

*FDA recommended dosing for Enthesis-related arthritis (ERA) or Pediatric PsA without coexistent Ps: Loading doses of 150 mg or 75 mg (depending on weight) at weeks 0, 1, 2, 3, 4; maintenance dose of 150 mg or 75 mg (depending on weight) every 4 weeks.

*FDA recommended dosing Plaque Psoriasis (Ps) with or without coexisting Psoriatic Arthritis (PsA): Adults: Loading doses of 300 mg at weeks 0, 1, 2, 3, 4; maintenance dose of 300 mg every 4 weeks; loading and maintenance doses of 150 mg every 4 weeks may be acceptable. Pediatric: Loading doses of 150 mg or 75 mg (depending on weight) at weeks 0, 1, 2, 3, 4; maintenance dose of 150 mg or 75 mg (depending on weight) every 4 weeks.

*FDA recommended dosing for Hidradenitis Suppurativa: Loading doses of 300 mg at weeks 0, 1, 2, 3, 4; maintenance dose of 300 mg every 4 weeks; may increase to 300 mg every 2 weeks for inadequate response.

*FDA recommended intravenous dosing for adult PsA, AS, and nr-axSpA: Optional 6 mg/kg loading dose followed by maintenance dosing of 1.75 mg/kg [max 300 mg] every 4 weeks thereafter.

*Initiation of therapy:

May approve a total of 5 (five) single pens (150 mg/mL) or 5 (five) single syringes (150 mg/mL or 75 mg/0.5 mL) in the first 35 days of treatment; **OR**

May approve a total of 5 (five) 2-pack pens (2 x 150 mg/mL) or 5 (five) 2-pack syringes (2 x 150 mg/mL) in the first 35 days of treatment; **OR**

May approve a total of 5 (five) 300 mg pens or 5 (five) 300 mg syringes in the first 35 days of treatment; **OR**

May approve enough single-dose vials for a single 6 mg/kg loading dose for initiating intravenous treatment in PsA, nr-axSpA, and AS.

^Maintenance therapy: May approve up to two 2-pack pens (2 x 150 mg/mL) OR up to two 2-pack syringes (2 x 150 mg/mL) OR up to two 300 mg pen/syringes every 28 days for individuals with Hidradenitis Suppurativa who do not respond to standard dosing of 300 mg every 4 weeks.

APPROVAL CRITERIA

Initial requests for Cosentyx (secukinumab) may be approved for the following:

- I. Ankylosing spondylitis (AS) when each of the following criteria are met:
 - A. Individual is 18 years of age or older with moderate to severe AS;**AND**
 - B. Individual has had an inadequate response to or is intolerant of conventional therapy [such as NSAIDs or nonbiologic disease-modifying anti-rheumatic drugs (DMARDs) (such as sulfasalazine)]; **OR**
 - C. Individual has a contraindication to NSAIDs or sulfasalazine;

OR

- II. Non-radiographic axial spondyloarthritis (nr-axSpA) when each of the following criteria are met:
 - A. Individual is 18 years of age or older with moderate to severe nr-axSpA; **AND**
 - B. Individual has had an inadequate response to or is intolerant of conventional therapy [such as NSAIDs or nonbiologic DMARDs (such as sulfasalazine)] (ACR 2019); **OR**
 - C. Individual has a contraindication to NSAIDs or sulfasalazine;

OR

- III. Plaque Psoriasis (Ps) (Psoriasis vulgaris) when each of the following criteria are met:
 - A. Individual is 6 years of age or older with chronic moderate to severe (that is, extensive or disabling) plaque Ps with either of the following: (AAD 2019):
 - 1. Plaque Ps (psoriasis vulgaris) involving greater than three percent (3%) body surface area (BSA); **OR**
 - 2. Plaque Ps (psoriasis vulgaris) involving less than or equal to three percent (3%) BSA involving sensitive areas or areas that significantly impact daily function (such as palms, soles of feet, head/neck, or genitalia);**AND**
 - B. Individual has had an inadequate response to or is intolerant of phototherapy or other systemic therapy (such as acitretin, cyclosporine, or methotrexate); **OR**
 - C. Individual has a contraindication to phototherapy, acitretin, cyclosporine, and methotrexate;

OR

- IV. Psoriatic arthritis (PsA) when each of the following criteria are met:
 - A. Individual is 2 years of age or older with moderate to severe PsA;**AND**
 - B. Individual has had an inadequate response to or is intolerant of conventional therapy [nonbiologic disease modifying anti-rheumatic drugs (DMARDs) (such as methotrexate, sulfasalazine, cyclosporine or leflunomide)] (ACR 2019); **OR**

- C. Individual has a contraindication to methotrexate, sulfasalazine, cyclosporine, and leflunomide;

OR

- V. Enthesitis-Related Arthritis (ERA) when each of the following criteria are met:
 - A. Individual is 4 years of age or older with moderate to severe ERA; **AND**
 - B. Individual has had an inadequate response to or is intolerant of conventional therapy [such as NSAIDs or nonbiologic DMARDs (such as methotrexate or sulfasalazine)];
OR
 - C. Individual has a contraindication to NSAIDs or sulfasalazine or methotrexate;

OR

- VI. Hidradenitis suppurativa (HS) when each of the following criteria are met:
 - A. Individual is 18 years of age or older; **AND**
 - B. Individual has moderate to severe HS; **AND**
 - C. Individual has had an inadequate response to or is intolerant of conventional therapy (such as oral antibiotics); **OR**
 - D. Individual has a contraindication to oral antibiotics.

Continuation requests for Cosentyx (secukinumab) may be approved if the following criterion is met:

- I. Individual has been receiving and is maintained on a stable dose of Cosentyx. Medication samples/coupons/discount cards are excluded from consideration as a trial.; **AND**
- II. There is clinically significant improvement or stabilization in clinical signs and symptoms of disease.

Requests for Cosentyx (secukinumab) may **not** be approved for the following:

- I. In combination with phototherapy; **OR**
- II. In combination with topical or oral JAK inhibitors, ozanimod, etrasimod, apremilast, deucravacitinib, or any of the following biologic immunomodulators: TNF antagonists, IL-23 inhibitors, other IL-17 inhibitors, vedolizumab, ustekinumab, abatacept, IL-1 inhibitors, IL-6 inhibitors, rituximab or natalizumab; **OR**
- III. Tuberculosis, other active serious infections, or a history of recurrent infections [repeat TB testing not required for ongoing therapy]; **OR**
- IV. If initiating therapy, individual has not had a tuberculin skin test (TST) or a Centers for Disease Control (CDC-) and Prevention -recommended equivalent test to evaluate for latent (unless switching therapy from another targeted immune modulator and no new risk factors); **OR**
- V. When the above criteria are not met and for all other indications.

Key References:

1. Alikhan A, Sayed C, Alavi A et al. North American clinical management guidelines for hidradenitis suppurativa: A publication from the United States and Canadian Hidradenitis Suppurativa Foundations: Part II: Topical, intralesional, and systemic medical management. *J Am Acad Dermatol*. 2019; 81:91-101.
2. Centers for Disease Control and Prevention (CDC). Tuberculosis (TB). Available at: <https://www.cdc.gov/tb/topic/basics/risk.htm>. Last updated: March 18, 2016. Accessed October 12, 2023.
3. DailyMed. Package inserts. U.S. National Library of Medicine, National Institutes of Health website. <http://dailymed.nlm.nih.gov/dailymed/about.cfm>. Accessed: October 12, 2023.
4. DrugPoints® System [electronic version]. Truven Health Analytics, Greenwood Village, CO. Updated periodically.
5. Lexi-Comp ONLINE™ with AHFS™, Hudson, Ohio: Lexi-Comp, Inc.; 2023; Updated periodically.
6. Menter A, Strober BE, Kaplan DH, et al. Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics. *J Am Acad Dermatol*. 2019; 80: 1029-72.
7. Singh JA, Guyatt G, Ogdie A, et al. 2018 American College of Rheumatology/National Psoriasis Foundation Guideline for the Treatment of Psoriatic Arthritis. *Arthritis Rheum*. 2019; 71(1): 5-32.
8. Ward MM, Deodhar A, Gensler LS, et al. 2019 Update of the American College of Rheumatology/Spondylitis Association of America/ Spondyloarthritis Research and Treatment Network Recommendations for the Treatment of Ankylosing Spondylitis and Nonradiographic Axial Spondyloarthritis. *Arthritis Rheumatol*. 2019; 71(10):1599-1613.

Federal and state laws or requirements, contract language, and Plan utilization management programs or policies may take precedence over the application of this clinical criteria.

No part of this publication may be reproduced, stored in a retrieval system or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from the health plan.